Patrys Limited · ASX:PAB
Patrys — Investor Presentation (March 2026)
14 slides from Patrys's investor presentation, Mar 31, 2026
Slide 1: Investor Presentation Update
ASX: PAB Investor Presentation Update March 2026 patrys.com 1
Slide 2: Disclaimer
Disclaimer The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested and no retur
Slide 3: A Faster, Lower-Risk Path to a >US$2B Delirium Market
A Faster, Lower-Risk Path to a >US$2B Delirium Market Proven Drug Reformulated for ICU Accelerated Quetiapine already widely used New proprietary Injectable Development Pathway in clinical practice formulation with patent FDA 505(b)(2) regulatory Safety and efficacy well protection extending
Slide 4: Board of Directors
Board of Directors Board combining biotech, clinical development and capital markets expertise ASX Governance Biotech Capital Markets, Finance Clinical Trial Healthcare & Biotech Commercialisation & Investor Relations Operations Investment Peter Christie Brian Leedman Leanne Kite Dino Cercarelli Dr
Slide 5: Delirium: Severe and Acute Brain Dysfunction
Delirium: Severe and Acute Brain Dysfunction Delirium: Severe and Acute Brain Dysfunction Confusion Cognitive Increased Decline Risk Of Dementia1 Disorientation Altered Thinking & Behavious Up to 80% of ICU patients experience 3 Forms delirium • Withdrawn (Hypoactive) • Mixed Estimated Serviceable A
Slide 6: The Problem: Current Treatment Challenges
The Problem: Current Treatment Challenges “OFF-LABEL” Quetiapine: Atypical • No approved drug Antipsychotic & Antipsychotic Benzodiazepine treatments • Haloperidol • Only available as oral formulation • Slow onset of action (1-2h) • Risperidone • Difficult to administer to delirium patients • Dexmed
Slide 7: Solution: Proprietary Injectable Quetiapine
Solution: Proprietary Injectable Quetiapine • Rapid control of acute agitation episodes • Faster resolution of delirium • Improved safety for patients and staff • Shorter ICU and hospital stays • Cost of care reduced Patrys Limited (ASX:PAB) 7
Slide 8: A Faster Path to Market
A Faster Path to Market Reformulation strategy enables faster, de-risked drug development 2–3× Higher success rate vs novel drugs 40–60% Lower cost & timeline Patrys Limited (ASX:PAB) 8
Slide 9: A Structurally De-Risked Opportunity
A Structurally De-Risked Opportunity Compared to a typical biotech program, this asset is de-risked across all major value drivers Risk Factor Typical Biotech Risk This Asset Investor Takeaway HIGH LOW Market Demand Open market with clear demand - no & Unmet Need • Competing with approved drugs • No
Slide 10: Accelerated Clinical Development Pathway
Accelerated Clinical Development Pathway Bridging Studies 2026 H1 2026 H2 2027 2028 Required • Human micro-dosing + 01 02 03 PBPK modelling Global pivotal ICU Pre-Study Phase 1A Phase 1B • Predict human dose and Preparation Clinical Trial Study delirium study administration • Finalise manufacturing
Slide 11: Clinical Development Timeline and Key Value Catalysts
Clinical Development Timeline and Key Value Catalysts Multiple near-term clinical and regulatory milestones Extensive existing Decades of clinical use of oral quetiapine expected over the next 18–24 months. clinical data significantly reduces technical and regulatory risk for the IV reformulation pr
Slide 12: Corporate Snapshot
Corporate Snapshot Capital Structure Share Price History Shares on issue 1 532,396,581 Share price 2 2.8c Market Opportunity ~US$2B Market capitalisation $15M Serviceable addressable Cash 3 $1.9M delirium treatment market Debt Nil Enterprise Value $14.5M Notes: 1. Shares on issue is shown undiluted.
Slide 13: A Faster, Lower-Risk Path to a >US$2B Delirium Market
A Faster, Lower-Risk Path to a >US$2B Delirium Market Proven Drug Reformulated for ICU Accelerated Quetiapine already widely used New proprietary Injectable Development Pathway in clinical practice formulation with patent FDA 505(b)(2) regulatory Safety and efficacy well protection extending
Slide 14: Contact
Patrys Limited (ASX:PAB) Proven drug, better delivery. De-risked investment. Contact Dr. Samantha South Phone: +61 421 117 241 Email: info@patrys.com Patrys Limited (ASX:PAB) patrys.com